Hansoh Pharmaceutical Group Company Limited
3692
Classifica tra le azioni
#971
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Prezzo delle azioni
$4.06
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$24.62B
Variazione (1 giorno)
1.15%
Variazione (1 anno)
-13.54%
Paese
CN
Scambia Hansoh Pharmaceutical Group Company Limited (3692)
Categoria
Healthcare
Margine operativo per Hansoh Pharmaceutical Group Company Limited (3692)
Margine operativo al October 2026 TTM: 37.52%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Hansoh Pharmaceutical Group Company Limited, il margine operativo attuale (TTM) è 37.52%. Alla fine del 2023, il margine operativo era 28.10%.
Storico del margine operativo per Hansoh Pharmaceutical Group Company Limited da 2016 a 2026
Margine operativo alla fine di ogni anno
| Anno | Margine Operativo | Cambia |
|---|---|---|
| 2026 (TTM) | 37.52% | 14.11% |
| 2024 | 32.88% | 17.01% |
| 2023 | 28.10% | -1.30% |
| 2022 | 28.47% | -2.33% |
| 2021 | 29.15% | -8.65% |
| 2020 | 31.91% | -0.34% |
| 2019 | 32.02% | 6.56% |
| 2018 | 30.05% | -3.62% |
| 2017 | 31.18% | -6.28% |
| 2016 | 33.27% | 0.00% |
Margine operativo per aziende simili o concorrenti
| Azienda | Margine Operativo | Differenza del margine operativo | Il paese |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -99.39% |
IN
|
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.